Giga-tronics Reports Results for the Fourth Quarter and FY

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Giga-tronics Reports Results for the Fourth Quarter and FY 2015

SAN RAMON, Calif., May 18, 2015 (GLOBE NEWSWIRE) -- Giga-tronics Incorporated (Nasdaq: GIGA ) reported today net sales for the fourth quarter of fiscal 2015 increased 48% to $4.3 million, as compared to $2.9 million for the fourth quarter of fiscal 2014. The increase in quarterly net sales was primarily due to a $771,000 increase in sales of radar filter components associated with two fighter jet programs, and $499,000 associated with initial customer acceptance of the Company's new Advanced Signal Generation System.

Net sales for the fiscal year 2015 increased 39% to $18.5 million, as compared to $13.3 million for the fiscal year 2014. The increase in annual net sales was primarily due to a $6.5 million nonrecurring engineering (NRE) order for YIG filters and a $2.4 million Naval Air Warfare Center (Navy) order for test equipment, both of which were received in the first quarter of fiscal 2015.

Net loss for the fourth quarter of fiscal 2015 was $1.4 million or $0.25 per fully diluted share. This net loss includes a one-time non-recurring and non-cash charge of approximately $1.2 million related to the issuance of new warrants. This compares to a net loss for the fourth quarter of fiscal 2014 of $1.3 million, or $0.25 per fully diluted share.

Net loss for fiscal year 2015 was $1.7 million or $0.32 per fully diluted share. This net loss includes a one-time non-recurring and non-cash charge of approximately $1.2 million related to the issuance of new warrants. Net loss for fiscal year 2014 was $3.7 million, or $0.74 per fully diluted share. The improvements to net loss when comparing fiscal 2015 to fiscal 2014 were primarily due to increased revenues from the NRE and Navy orders, along with improved gross margins and lower operating expenses.

Non-GAAP net income for the fourth quarter of fiscal 2015 was $179,000, or $0.03 per fully diluted share, compared to a non-GAAP net loss for the fourth quarter of fiscal 2014 of $1.2 million, or $0.23 per fully diluted share.

Non-GAAP net income for fiscal 2015 was $538,000 or $0.10 per fully diluted share, compared to a non-GAAP net loss for fiscal 2014 of $3.2 million or $0.64 per fully diluted share. Non-GAAP net income/loss excludes non-cash expenses associated with the derivative revaluation, warrant charge expense and discount accretion of debt and warrant agreements as well as stock-based compensation (1).

Mr. John Regazzi, the Company's CEO stated, "We achieved an important milestone in the fourth quarter of fiscal 2015 when after years in development, two customers accepted their initial units of our Advanced Signal Generation System. With it now in production, the Advanced Signal Generation System should start contributing to the Company's long term success."

Mr. Regazzi concluded, "I am very pleased to see the Company achieving non-GAAP profits for the past three fiscal quarters and for all of fiscal 2015. The non-GAAP profits and the $1.5 million of net proceeds received from Alara Capital AVI II, LLC from their recent exercise of warrants has greatly improved the Company's financial viability."

Giga-tronics will host a conference call today at 4:30 p.m. ET to discuss the fourth quarter results. To participate in the call, dial (888) 424-8151 or (847) 585-4422, and enter PIN Code 9178731#. The call will also be broadcast over the internet at www.gigatronics.com under "Investor Relations." The conference call discussion reflects management's views as of May 18, 2015.

Giga-tronics is a publicly held company, traded on the NASDAQ Capital Market under the symbol "GIGA". Giga-tronics produces instruments, subsystems and sophisticated microwave components that have broad applications in defense electronics, aeronautics and wireless telecommunications.

This press release contains forward-looking statements concerning operating results, future orders, sales of new products, long term growth, shipments, and customer acceptance of new products. Actual results may differ significantly due to risks and uncertainties, such as: delays in customer orders for the new Advanced Signal Generation System, receipt or timing of future orders, cancellations or deferrals, our ability to continue as a going concern, our need for additional financing, possible delisting from trading on the NASDAQ Capital Market and moving to the OTCQB marketplace; the volatility in the market price of our common stock; and general market conditions. For further discussion, see Giga-tronics' most recent annual report on Form 10-K for the fiscal year ended March 29, 2014, Part I, under the heading "Risk Factors" and Part II, under the heading "Management's Discussion and Analysis of Financial Condition and Results of Results of Operations".

(1) Non-GAAP net income/loss and non-GAAP earnings/loss per share, differ from net income/loss and earnings/loss per share determined in accordance with GAAP (Generally Accepted Accounting Principles in the United States). Non-GAAP net income/loss and non-GAAP earnings/loss per share for the quarter and fiscal year ended March 28, 2015 exclude the effects of the revaluation of the derivative liability as well as the accretion of the discounts on debt and warrant notes entered into in March and June of 2014. Non-GAAP net income/loss and non-GAAP earnings/loss per share for the quarter and fiscal year ended March 28, 2015 also exclude the effects of a warrant charge expense related to the issuance of new warrants issued in February 2015. These numbers also exclude the impact of Stock Based Compensation which is also excluded from non-GAAP operating margin, operating expenses and operating income/loss. These non-GAAP financial measures are not prepared in accordance with GAAP and should not be considered as a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP. A schedule reconciling non-GAAP financial measures is included in the financial information appearing at the end of this press release. Giga-tronics utilizes both GAAP and non-GAAP financial measures to assess what it believes to be its core operating performance to evaluate and manage its internal business and to assist in making financial operating decisions. Giga-tronics believes that the inclusion of non-GAAP financial measures, together with GAAP measures, provides investors with an alternative presentation useful to investors' understanding of Giga-tronics' core operating results and trends. Additionally, Giga-tronics believes that the inclusion of non-GAAP measures, together with GAAP measures, provides investors with an additional dimension of comparability to similar companies. However, investors should be aware that non-GAAP financial measures utilized by other companies are not likely to be comparable in most cases to the non-GAAP financial measures used by Giga-tronics.

 
GIGA-TRONICS INCORPORATED
CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)
(In thousands except share data)  March 28, 2015  March 29, 2014
Assets    
Current assets:    
Cash and cash-equivalents  $ 1,170  $ 1,059
Trade accounts receivable, net of allowance of $45 and $44, respectively 2,354  1,846
Inventories, net 3,365  3,321
Prepaid expenses and other current assets 373  349
Total current assets 7,262 6,575
Property and equipment, net 718  949
Other long term assets 74 69
Total assets $ 8,054  $ 7,593
Liabilities and shareholders' equity    
Current liabilities:    
Line of credit  $ —  $ 1,165
Current portion of long term debt 811 200
Accounts payable 973  1,430
Accrued payroll and benefits 678  755
Deferred revenue 1,127  1,329
Deferred rent 127  104
Capital lease obligations 69  147
Other current liabilities 501  472
Total current liabilities 4,286  5,602
Long term loan and warrant debt, net of discounts 392  672
Derivative Liability-at estimated fair value 252 128
Long term obligations - deferred rent 111  237
Long term obligations - capital lease 58  77
Total liabilities 5,099  6,716
     
Shareholders' equity:    
Convertible preferred stock of no par value;    
Authorized - 1,000,000 shares    
Series A - designated 250,000 shares; no shares at March 28, 2015 and March 29, 2014 issued and outstanding — —
Series B, C, D - designated 19,500 shares; 18,533.31 shares at  March 28, 2015 and March 29, 2014 issued and outstanding;  (liquidation preference of $3,540) 2,911 2,911
Common stock of no par value;    
Authorized - 40,000,000 shares; 6,706,065 shares at March 28, 2015 and 5,181,247 at March 29, 2014 issued and outstanding 19,975 16,224
Accumulated deficit (19,931)  (18,258)
Total shareholders' equity 2,955  877
Total liabilities and shareholders' equity $ 8,054  $ 7,593
 
 
GIGA-TRONICS INCORPORATED
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)
  Three Month Periods Ended Years Ended
  March 28, March 29, March 28, March 29,
(In thousands except share and per share data)  2015  2014  2015  2014
Net sales $ 4,325  $ 2,905 $ 18,452  $ 13,309
Cost of sales 2,344  2,139 10,445 8,811
Gross margin 1,981 766 8,007 4,498
         
Operating expenses:        
Engineering 647 857 3,210 3,897
Selling, general and administrative 1,382  1,135 4,783 4,809
Restructuring — (29) — 331
Total operating expenses 2,029  1,963 7,993 9,037
         
Operating income/(loss) (48)  (1,197) 14   (4,539)
         
Gain on sale of product line — — — 913
Loss on adjustment of derivative liability to fair value (17) — — —
Warrant expense (1,232) — (1,232) —
Other loss — (16) (2) (8)
         
Interest expense, net (55)  (53) (254)   (106)
Accretion of loan and warrant debt discounts (38) — (152) —
         
Loss before income taxes (1,390)  (1,266) (1,626)  (3,740)
Provision for income taxes — — 47  2
Net loss $ (1,390) $ (1,266) $ (1,673)  $ (3,742)
         
Loss per common share – basic $ (0.25) $ (0.25) $ (0.32) $ (0.74)
Loss per common share – diluted $ (0.25) $ (0.25) $ (0.32) $ (0.74)
         
Weighted average common shares used in per share calculation:        
Basic 5,616  5,060 5,279  5,058
Diluted 5,616  5,060 5,279 5,058
 
 
RECONCILIATION OF NET LOSS TO NON-GAAP NET INCOME/(LOSS)
(Unaudited in thousands, except for share and per share data)
  Three Month Periods Ended Years Ended
  March 28, March 29, March 28, March 29,
  2015 2014 2015 2014
Net loss $ (1,390) $ (1,266) $ (1,673) $ (3,742)
Adjustments to reconcile net loss to non-GAAP net income/(loss):        
Warrant charge expense 1,232 — 1,232 —
Stock based compensation expense 282 96 827 494
(Gain) / loss on adjustment of derivative liability to fair value 17 — — —
Accretion of loan and warrant debt discounts 38 — 152 —
Non-GAAP net income/(loss) $ 179 $ (1,170) $ 538 $ (3,248)
Non-GAAP earnings/(loss) per common share-basic $  0.03 $ (0.23) $ 0.10 $ (0.64)
Non-GAAP earnings/(loss) per common share- diluted $  0.03 $ (0.23) $ 0.10 $ (0.64)
Shares used in the calculation of non-GAAP earnings/(loss) per share:        
Basic 5,616 5,060 5,279 5,058
Diluted 5,616 5,060 5,279 5,058
 
 
GIGA-TRONICS INCORPORATED
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)
   
  Three Month Periods Ended
  March 28, December 27, September 27, June 28,
(In thousands except share and per share data)  2015  2014  2014  2014
Net sales $ 4,325  $ 4,509  $ 5,110  $  4,508
Cost of sales 2,344 2,637 2,794 2,670
Gross margin 1,981 1,872 2,316 1,838
         
Operating expenses:        
Engineering 647 672 962 929
Selling, general and administrative 1,382 1,133 1,241 1,027
Total operating expenses 2,029 1,805 2,203 1,956
         
Operating income/(loss) (48) 67 113 (118)
         
Gain / (loss) on adjustment of derivative liability to fair value (17) 107 103 (193)
Other (expense) income (1,232) — — (2)
Interest expense, net (55) (62) (78) (59)
Accretion of loan and warrant debt discounts (38) (45) (45) (24)
Income/(loss) before income taxes (1,390) 67 93 (396)
Provision for income taxes — — — 47
Net income/(loss) $ (1,390)  $ 67 $ 93  $ (443)
         
Earnings/(loss) per common share – basic  $ (0.25)  $ 0.01  $ 0.01  $ (0.09)
Earnings/(loss) per common share – diluted  $ (0.25)  $ 0.01  $ 0.01  $ (0.09)
         
Weighted average common shares used in per share calculation:        
Basic 5,616 5,208 5,178 5,113
Diluted 5,616 5,463 5,720 5,113
 
 
RECONCILIATION OF NET INCOME/(LOSS) TO NON-GAAP NET INCOME/(LOSS)
(Unaudited in thousands, except share and  per share data)
  Three Month Periods Ended
  March 28, December 27, September 27, June 28,
  2015 2014 2014 2014
Net income/(loss) $ (1,390) $ 67 $ 93 $ (443)
Adjustments to reconcile net income/(loss) to non-GAAP net income/(loss):        
Warrant charge expense 1,232 — — —
Stock based compensation expense 282 234 227 84
(Gain) / loss on adjustment of derivative liability to fair value 17 (107) (103) 193
Accretion of loan and warrant debt discounts 38 45 45 24
Non-GAAP net income/(loss) $ 179 $ 239 $ 262 $ (142)
Non-GAAP earnings/(loss) per common share-basic  $ 0.03 $ 0.03 $ 0.04 $ (0.03)
Non-GAAP earnings/(loss) per common share- diluted  $ 0.03 $ 0.03 $ 0.03 $ (0.03)
Shares used in the calculation of non-GAAP earnings/(loss) per share:        
Basic 5,616 5,208 5,178 5,113
Diluted 5,616 5,463 5,720 5,113

Steven D. Lance Vice President of Finance/Chief Financial Officer (925) 302-1056

Scroll down for more posts ▼

Top 10 Most Recent News Articles

PHONO's 150 MW RE+ Win Tests Its U.S. Solar Staying Power

Updated Category News Views 534

A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...

Continue Reading
Cardiovalve's Three-Year Data Clears a Crucial EU Hurdle

Updated Category News Views 98

A failing tricuspid valve is not a spreadsheet problem, and that matters before anybody gets carried away with a glossy conference presentation. Venus Medtech's Cardiovalve unit has reported results from TARGET in a population that was old, sick and largely out of good surgical options. That is precisely where a less invasive replacement therapy has to prove it can do...

Continue Reading
NatGasHub’s 391% Growth Signals a Real Pipeline Shift

Updated Category News Views 445

Three hundred-plus pipelines is a lot of messy plumbing to tame, and NatGasHub has apparently found a lucrative way to do it. The Houston software company landed at No. 182 on Deloitte’s 2026 Technology Fast 500 after reporting 391% revenue growth from 2022 through 2025. That is a serious number, even in a ranking built to showcase companies sprinting uphill. More...

Continue Reading
DataBeyond Puts AI Sorting Before a Waste Mountain

Updated Category News Views 191

Trash is a lousy place to look for technological glamour, which is precisely why DataBeyond's COP31 appearance deserves a sober look. On November 19 in Antalya, Türkiye, the Hangzhou-based equipment provider used a China Pavilion event to lay out its case for AI, optical sensing and robots in resource recovery. That is not a magic-green headline. It is a practical...

Continue Reading
Ajman Memory Gives Heritage a Durable Digital Backbone

Updated Category News Views 303

Archives usually get applause only after somebody realizes a piece of history has vanished. Ajman is trying to skip that miserable part. During the Ajman Media Forum 2026, held November 18 and 19 at the Emirates Hospitality Centre, the emirate launched Ajman Memory, a project built to collect, document and preserve photographs, papers and video recording its development....

Continue Reading
PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 410

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
AutoShop Answers Extends 2027 Training Into Fridays

Updated Category News Views 55

A repair bay can hum all day while the back office quietly bleeds profit. That unglamorous reality is why AutoShop Answers adding nine Friday specialty classes to its 2027 Key2Key Weekend calendar deserves a closer look. This is not a new tool chest or some vague motivational roadshow; it is an attempt to give independent shop owners an extra day to work on the pieces...

Continue Reading
FASTEN Data Offers an Early Look at Ladera Closure

Updated Category News Views 137

Femoral access may be the unglamorous part of a valve procedure, but it is where an otherwise tidy case can turn ugly in a hurry. That makes Ladera Medical's full FASTEN data worth a careful look. The company reported results in 55 patients undergoing transfemoral TAVR/TAVI, and the numbers presented at London Valves 2026 suggest its large-bore closure system may address...

Continue Reading
UAE Ties Diplomacy, Media and AI Into a Shared Signal

Updated Category News Views 128

Influence is getting harder to measure, and easier to squander, which is why the message from Ajman deserves more than a polite nod. At the 2026 Ajman Media Forum, THE SIGNAL, Foreign Affairs Undersecretary Omar Obaid Alhesan Alshamsi made the UAE’s position plain: diplomacy and media are no longer separate lanes. Both operate on words, context, trust and the difficult...

Continue Reading
Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 666

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading

Top 5 Most Recently Viewed Articles

Regulatory T-Cells Market Growth Driven by New Therapies

Updated Category News Views 217

Insights into the Regulatory T-Cells Market Growth The landscape of the Treg therapy market is rapidly evolving as companies globally actively develop innovative regulatory T-cell therapies to treat various critical conditions. These include systemic lupus erythematosus (SLE), lupus nephritis, atopic dermatitis, rheumatoid arthritis, psoriasis, progressive multiple...

Continue Reading
Natural Grocers Unveils Autumnfest Super Savings Event

Updated Category News Views 67

Natural Grocers Introduces Autumnfest Savings Event As the autumn leaves begin to fall, Natural Grocers invites shoppers to revel in the festivities of the season with their exciting Autumnfest Savings Event. This annual celebration promises customers an incredible opportunity to enjoy significant discounts, free samples, and delightful seasonal recipes. With savings of...

Continue Reading
Anthem Blue Cross Commits $10 Million for Wildfire Relief

Updated Category News Views 270

Anthem Blue Cross Generously Assists Communities Affected by Wildfires For over eight decades, Anthem Blue Cross has maintained a strong presence in California, prioritizing the health and well-being of its residents. Our focus has always been on putting people first, as we acknowledge the struggles that come with disasters that can significantly impact the lives of our...

Continue Reading
Corporate Legal Departments Face Major Workforce Challenges

Updated Category News Views 179

Corporate Legal Departments Face Major Workforce Challenges In the evolving landscape of corporate legal departments, a significant wave of attrition is looming as in-house attorneys express a desire to seek better opportunities. The increase in workloads, coupled with concerns about artificial intelligence and limited career advancement prospects, has prompted many legal...

Continue Reading
Currax Achieves FDA Approval for Enhanced CONTRAVE Supply Chain

Updated Category News Views 411

Currax Expands Manufacturing Capabilities for CONTRAVE Currax Pharmaceuticals LLC, a focused specialty pharmaceutical company, recently announced a significant milestone in its operations. The U.S. Food and Drug Administration (FDA) has granted approval for a second manufacturing facility dedicated to the production of CONTRAVE (naltrexone HCl/bupropion HCl), a leading...

Continue Reading